- Home
- PMCB vs BRTX Comparison
PMCB vs BRTX Comparison
Compare PMCB & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- BRTX
- Stock Information
- Founded
- PMCB 1996
- BRTX 1997
- Country
- PMCB United States
- BRTX United States
- Employees
- PMCB N/A
- BRTX N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- BRTX Managed Health Care
- Sector
- PMCB Health Care
- BRTX Health Care
- Exchange
- PMCB Nasdaq
- BRTX Nasdaq
- Market Cap
- PMCB 13.9M
- BRTX 11.3M
- IPO Year
- PMCB N/A
- BRTX N/A
- Fundamental
- Price
- PMCB $1.62
- BRTX $1.41
- Analyst Decision
- PMCB
- BRTX Strong Buy
- Analyst Count
- PMCB 0
- BRTX 1
- Target Price
- PMCB N/A
- BRTX $18.00
- AVG Volume (30 Days)
- PMCB 13.7K
- BRTX 100.5K
- Earning Date
- PMCB 12-24-2024
- BRTX 11-12-2024
- Dividend Yield
- PMCB N/A
- BRTX N/A
- EPS Growth
- PMCB N/A
- BRTX N/A
- EPS
- PMCB 0.74
- BRTX N/A
- Revenue
- PMCB N/A
- BRTX $377,000.00
- Revenue This Year
- PMCB N/A
- BRTX $482.76
- Revenue Next Year
- PMCB N/A
- BRTX $212.24
- P/E Ratio
- PMCB $2.25
- BRTX N/A
- Revenue Growth
- PMCB N/A
- BRTX 189.55
- 52 Week Low
- PMCB $1.39
- BRTX $1.03
- 52 Week High
- PMCB $2.58
- BRTX $3.67
- Technical
- Relative Strength Index (RSI)
- PMCB 45.07
- BRTX 41.13
- Support Level
- PMCB $1.61
- BRTX $1.40
- Resistance Level
- PMCB $1.81
- BRTX $1.60
- Average True Range (ATR)
- PMCB 0.11
- BRTX 0.10
- MACD
- PMCB 0.00
- BRTX 0.00
- Stochastic Oscillator
- PMCB 43.64
- BRTX 42.86
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.